BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

577 related articles for article (PubMed ID: 22010914)

  • 1. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis.
    Havlir DV; Kendall MA; Ive P; Kumwenda J; Swindells S; Qasba SS; Luetkemeyer AF; Hogg E; Rooney JF; Wu X; Hosseinipour MC; Lalloo U; Veloso VG; Some FF; Kumarasamy N; Padayatchi N; Santos BR; Reid S; Hakim J; Mohapi L; Mugyenyi P; Sanchez J; Lama JR; Pape JW; Sanchez A; Asmelash A; Moko E; Sawe F; Andersen J; Sanne I;
    N Engl J Med; 2011 Oct; 365(16):1482-91. PubMed ID: 22010914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis.
    Blanc FX; Sok T; Laureillard D; Borand L; Rekacewicz C; Nerrienet E; Madec Y; Marcy O; Chan S; Prak N; Kim C; Lak KK; Hak C; Dim B; Sin CI; Sun S; Guillard B; Sar B; Vong S; Fernandez M; Fox L; Delfraissy JF; Goldfeld AE;
    N Engl J Med; 2011 Oct; 365(16):1471-81. PubMed ID: 22010913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integration of antiretroviral therapy with tuberculosis treatment.
    Abdool Karim SS; Naidoo K; Grobler A; Padayatchi N; Baxter C; Gray AL; Gengiah T; Gengiah S; Naidoo A; Jithoo N; Nair G; El-Sadr WM; Friedland G; Abdool Karim Q
    N Engl J Med; 2011 Oct; 365(16):1492-501. PubMed ID: 22010915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti.
    Severe P; Juste MA; Ambroise A; Eliacin L; Marchand C; Apollon S; Edwards A; Bang H; Nicotera J; Godfrey C; Gulick RM; Johnson WD; Pape JW; Fitzgerald DW
    N Engl J Med; 2010 Jul; 363(3):257-65. PubMed ID: 20647201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
    ; Danel C; Moh R; Gabillard D; Badje A; Le Carrou J; Ouassa T; Ouattara E; Anzian A; Ntakpé JB; Minga A; Kouame GM; Bouhoussou F; Emieme A; Kouamé A; Inwoley A; Toni TD; Ahiboh H; Kabran M; Rabe C; Sidibé B; Nzunetu G; Konan R; Gnokoro J; Gouesse P; Messou E; Dohoun L; Kamagate S; Yao A; Amon S; Kouame AB; Koua A; Kouamé E; Ndri Y; Ba-Gomis O; Daligou M; Ackoundzé S; Hawerlander D; Ani A; Dembélé F; Koné F; Guéhi C; Kanga C; Koule S; Séri J; Oyebi M; Mbakop N; Makaila O; Babatunde C; Babatounde N; Bleoué G; Tchoutedjem M; Kouadio AC; Sena G; Yededji SY; Assi R; Bakayoko A; Mahassadi A; Attia A; Oussou A; Mobio M; Bamba D; Koman M; Horo A; Deschamps N; Chenal H; Sassan-Morokro M; Konate S; Aka K; Aoussi E; Journot V; Nchot C; Karcher S; Chaix ML; Rouzioux C; Sow PS; Perronne C; Girard PM; Menan H; Bissagnene E; Kadio A; Ettiegne-Traore V; Moh-Semdé C; Kouame A; Massumbuko JM; Chêne G; Dosso M; Domoua SK; N'Dri-Yoman T; Salamon R; Eholié SP; Anglaret X
    N Engl J Med; 2015 Aug; 373(9):808-22. PubMed ID: 26193126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prednisone for the Prevention of Paradoxical Tuberculosis-Associated IRIS.
    Meintjes G; Stek C; Blumenthal L; Thienemann F; Schutz C; Buyze J; Ravinetto R; van Loen H; Nair A; Jackson A; Colebunders R; Maartens G; Wilkinson RJ; Lynen L;
    N Engl J Med; 2018 Nov; 379(20):1915-1925. PubMed ID: 30428290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Timing of initiation of antiretroviral drugs during tuberculosis therapy.
    Abdool Karim SS; Naidoo K; Grobler A; Padayatchi N; Baxter C; Gray A; Gengiah T; Nair G; Bamber S; Singh A; Khan M; Pienaar J; El-Sadr W; Friedland G; Abdool Karim Q
    N Engl J Med; 2010 Feb; 362(8):697-706. PubMed ID: 20181971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The immune reconstitution inflammatory syndrome after antiretroviral therapy initiation in patients with tuberculosis: findings from the SAPiT trial.
    Naidoo K; Yende-Zuma N; Padayatchi N; Naidoo K; Jithoo N; Nair G; Bamber S; Gengiah S; El-Sadr WM; Friedland G; Abdool Karim S
    Ann Intern Med; 2012 Sep; 157(5):313-24. PubMed ID: 22944873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy.
    Le T; Wright EJ; Smith DM; He W; Catano G; Okulicz JF; Young JA; Clark RA; Richman DD; Little SJ; Ahuja SK
    N Engl J Med; 2013 Jan; 368(3):218-30. PubMed ID: 23323898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic or Test-Guided Treatment for Tuberculosis in HIV-Infected Adults.
    Blanc FX; Badje AD; Bonnet M; Gabillard D; Messou E; Muzoora C; Samreth S; Nguyen BD; Borand L; Domergue A; Rapoud D; Natukunda N; Thai S; Juchet S; Eholié SP; Lawn SD; Domoua SK; Anglaret X; Laureillard D;
    N Engl J Med; 2020 Jun; 382(25):2397-2410. PubMed ID: 32558469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD4+ count-guided interruption of antiretroviral treatment.
    ; El-Sadr WM; Lundgren J; Neaton JD; Gordin F; Abrams D; Arduino RC; Babiker A; Burman W; Clumeck N; Cohen CJ; Cohn D; Cooper D; Darbyshire J; Emery S; Fätkenheuer G; Gazzard B; Grund B; Hoy J; Klingman K; Losso M; Markowitz N; Neuhaus J; Phillips A; Rappoport C
    N Engl J Med; 2006 Nov; 355(22):2283-96. PubMed ID: 17135583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.
    ; Lundgren JD; Babiker AG; Gordin F; Emery S; Grund B; Sharma S; Avihingsanon A; Cooper DA; Fätkenheuer G; Llibre JM; Molina JM; Munderi P; Schechter M; Wood R; Klingman KL; Collins S; Lane HC; Phillips AN; Neaton JD
    N Engl J Med; 2015 Aug; 373(9):795-807. PubMed ID: 26192873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced Prophylaxis plus Antiretroviral Therapy for Advanced HIV Infection in Africa.
    Hakim J; Musiime V; Szubert AJ; Mallewa J; Siika A; Agutu C; Walker S; Pett SL; Bwakura-Dangarembizi M; Lugemwa A; Kaunda S; Karoney M; Musoro G; Kabahenda S; Nathoo K; Maitland K; Griffiths A; Thomason MJ; Kityo C; Mugyenyi P; Prendergast AJ; Walker AS; Gibb DM;
    N Engl J Med; 2017 Jul; 377(3):233-245. PubMed ID: 28723333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial.
    Grinsztejn B; Hosseinipour MC; Ribaudo HJ; Swindells S; Eron J; Chen YQ; Wang L; Ou SS; Anderson M; McCauley M; Gamble T; Kumarasamy N; Hakim JG; Kumwenda J; Pilotto JH; Godbole SV; Chariyalertsak S; de Melo MG; Mayer KH; Eshleman SH; Piwowar-Manning E; Makhema J; Mills LA; Panchia R; Sanne I; Gallant J; Hoffman I; Taha TE; Nielsen-Saines K; Celentano D; Essex M; Havlir D; Cohen MS;
    Lancet Infect Dis; 2014 Apr; 14(4):281-90. PubMed ID: 24602844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Antiretroviral Therapy Initiated One Week after Tuberculosis Therapy in Patients with CD4 Counts < 200 Cells/μL: TB-HAART Study, a Randomized Clinical Trial.
    Amogne W; Aderaye G; Habtewold A; Yimer G; Makonnen E; Worku A; Sonnerborg A; Aklillu E; Lindquist L
    PLoS One; 2015; 10(5):e0122587. PubMed ID: 25966339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tuberculosis immune reconstitution inflammatory syndrome in A5221 STRIDE: timing, severity, and implications for HIV-TB programs.
    Luetkemeyer AF; Kendall MA; Nyirenda M; Wu X; Ive P; Benson CA; Andersen JW; Swindells S; Sanne IM; Havlir DV; Kumwenda J;
    J Acquir Immune Defic Syndr; 2014 Apr; 65(4):423-8. PubMed ID: 24226057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integration and task shifting for TB/HIV care and treatment in highly resource-scarce settings: one size may not fit all.
    Van Rie A; Patel MR; Nana M; Vanden Driessche K; Tabala M; Yotebieng M; Behets F
    J Acquir Immune Defic Syndr; 2014 Mar; 65(3):e110-7. PubMed ID: 24091692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Simultaneous treatment of HIV and tuberculosis is possible and necessary].
    von der Maase S; Gerstoft J; Wejse C
    Ugeskr Laeger; 2014 Feb; 176(6A):V03130163. PubMed ID: 25347439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors for early mortality on antiretroviral therapy in advanced HIV-infected adults.
    Bisson GP; Ramchandani R; Miyahara S; Mngqibisa R; Matoga M; Ngongondo M; Samaneka W; Koech L; Naidoo K; Rassool M; Kirui F; Banda P; Mave V; Kadam D; Leger P; Henestroza G; Manabe YC; Bao J; Kumwenda J; Gupta A; Hosseinipour MC;
    AIDS; 2017 Oct; 31(16):2217-2225. PubMed ID: 28742529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time to initiate antiretroviral therapy between 4 weeks and 12 weeks of tuberculosis treatment in HIV-infected patients: results from the TIME study.
    Manosuthi W; Mankatitham W; Lueangniyomkul A; Thongyen S; Likanonsakul S; Suwanvattana P; Thawornwan U; Suntisuklappon B; Nilkamhang S; Sungkanuparph S;
    J Acquir Immune Defic Syndr; 2012 Aug; 60(4):377-83. PubMed ID: 22592586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.